This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, Y. Articles by Mahley, R. W. Search for Related Content PubMed PubMed Citation Articles by Huang, Y. Articles by Mahley, R. W. Related Collections Biochemistry and metabolism Genetically altered mice Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2952.)
© 1999 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Overexpression of Apolipoprotein E3 in Transgenic Rabbits Causes Combined Hyperlipidemia by Stimulating Hepatic VLDL Production and Impairing VLDL Lipolysis

Yadong Huang; Zhong-Sheng Ji; Walter J. Brecht; Stanley C. Rall, Jr; John M. Taylor; Robert W. Mahley

From the Gladstone Institute of Cardiovascular Disease (Y.H., Z.-S..J., W.J.B., S.C.R., J.M.T., R.W.M.), the Cardiovascular Research Institute (Y.H., J.M.T., R.W.M.), and the Departments of Physiology (J.M.T.), Pathology (R.W.M.), and Medicine (R.W.M.), University of California, San Francisco.

Correspondence to Yadong Huang, MD, PhD, Gladstone Institute of Cardiovascular Disease, PO Box 419100, San Francisco, CA 94141-9100.

Abstract—The differential effects of overexpression of human apolipoprotein (apo) E3 on plasma cholesterol and triglyceride metabolism were investigated in transgenic rabbits expressing low (<10 mg/dL), medium (10 to 20 mg/dL), or high (>20 mg/dL) levels of apoE3. Cholesterol levels increased progressively with increasing levels of apoE3, whereas triglyceride levels were not significantly affected at apoE3 levels up to 20 mg/dL but were markedly increased at levels of apoE3 >20 mg/dL. The medium expressers had marked hypercholesterolemia (up to 3- to 4-fold over nontransgenics), characterized by an increase in low density lipoprotein (LDL) cholesterol, while the low expressers had only slightly increased plasma cholesterol levels. The medium expressers displayed an 18-fold increase in LDL but also had a 2-fold increase in hepatic very low density lipoprotein (VLDL) triglyceride production, an 8-fold increase in VLDL apoB, and a moderate decrease in the ability of the VLDL to be lipolyzed. However, plasma clearance of VLDL was increased, likely because of the increased apoE3 content. The increase in LDL appears to be due to an enhanced competition of VLDL for LDL receptor binding and uptake, resulting in the accumulation of LDL. The combined hyperlipidemia of the apoE3 high expressers (>20 mg/dL) was characterized by a 19-fold increase in LDL cholesterol but also a 4-fold increase in hepatic VLDL triglyceride production associated with a marked elevation of plasma VLDL triglycerides, cholesterol, and apoB100 (4-, 9-, and 25-fold over nontransgenics, respectively). The VLDL from the high expressers was much more enriched in apoE3 and markedly depleted in apoC-II, which contributed to a >60% inhibition of VLDL lipolysis. The combined effects of stimulated VLDL production and impaired VLDL lipolysis accounted for the increases in plasma triglyceride and VLDL concentrations in the apoE3 high expressers. The hyperlipidemic apoE3 rabbits have phenotypes similar to those of familial combined hyperlipidemia, in which VLDL overproduction is a major biochemical feature. Overall, elevated expression of apoE3 appears to determine plasma lipid levels by stimulating hepatic VLDL production, enhancing VLDL clearance, and inhibiting VLDL lipolysis. Thus, the differential expression of apoE may, within a rather narrow range of concentrations, play a critical role in modulating plasma cholesterol and triglyceride levels and may represent an important determinant of specific types of hyperlipoproteinemia.

Key Words: apoB • lipoprotein lipase • VLDL clearance • hypertriglyceridemia

This article has been cited by other articles:

				G. S. Getz and C. A. Reardon Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall J. Lipid Res., April 1, 2009; 50(Supplement): S156 - S161. [Abstract] [Full Text] [PDF]

				D. A. Blasiole, A. T. Oler, and A. D. Attie Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB J. Biol. Chem., April 25, 2008; 283(17): 11374 - 11381. [Abstract] [Full Text] [PDF]

				R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 190 - 196. [Abstract] [Full Text] [PDF]

				D. S. Christidis, E. N. Liberopoulos, A. I. Kakafika, G. A. Miltiadous, M. Cariolou, E. S. Ganotakis, D. P. Mikhailidis, and M. S. Elisaf The effect of apolipoprotein e polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 211 - 221. [Abstract] [PDF]

				N. A. Braun, P. J. Mohler, K. H. Weisgraber, A. H. Hasty, M. F. Linton, P. G. Yancey, Y. R. Su, S. Fazio, and L. L. Swift Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells J. Lipid Res., June 1, 2006; 47(6): 1176 - 1186. [Abstract] [Full Text] [PDF]

				A. H. Hasty, M. R. Plummer, K. H. Weisgraber, M. F. Linton, S. Fazio, and L. L. Swift The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I J. Lipid Res., July 1, 2005; 46(7): 1433 - 1439. [Abstract] [Full Text] [PDF]

				M. H. Farkas, K. H. Weisgraber, V. L. Shepherd, M. F. Linton, S. Fazio, and L. L. Swift The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment: evidence for multiple redundant pathways J. Lipid Res., August 1, 2004; 45(8): 1546 - 1554. [Abstract] [Full Text] [PDF]

				K. Ikewaki, W. Cain, F. Thomas, R. Shamburek, L. A. Zech, D. Usher, H. B. Brewer Jr., and D. J. Rader Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency J. Lipid Res., July 1, 2004; 45(7): 1302 - 1311. [Abstract] [Full Text] [PDF]

				M. H. Farkas, L. L. Swift, A. H. Hasty, M. F. Linton, and S. Fazio The Recycling of Apolipoprotein E in Primary Cultures of Mouse Hepatocytes. EVIDENCE FOR A PHYSIOLOGIC CONNECTION TO HIGH DENSITY LIPOPROTEIN METABOLISM J. Biol. Chem., March 7, 2003; 278(11): 9412 - 9417. [Abstract] [Full Text] [PDF]

				S. Vega-Lopez, H. C. Freake, and M. L. Fernandez Sex and Hormonal Status Modulate the Effects of Psyllium on Plasma Lipids and Monocyte Gene Expression in Humans J. Nutr., January 1, 2003; 133(1): 67 - 70. [Abstract] [Full Text] [PDF]

				H. N. Ginsberg New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism Circulation, October 15, 2002; 106(16): 2137 - 2142. [Full Text] [PDF]

				J. S. Cohn, M. Tremblay, R. Batal, H. Jacques, L. Veilleux, C. Rodriguez, P. H. R. Barrett, D. Dubreuil, M. Roy, L. Bernier, et al. Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia J. Lipid Res., September 1, 2002; 43(9): 1464 - 1471. [Abstract] [Full Text] [PDF]

				M. E. Hinsdale, P. M. Sullivan, H. Mezdour, and N. Maeda ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice J. Lipid Res., September 1, 2002; 43(9): 1520 - 1528. [Abstract] [Full Text] [PDF]

				E. A. Fisher and H. N. Ginsberg Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins J. Biol. Chem., May 10, 2002; 277(20): 17377 - 17380. [Full Text] [PDF]

				R. L. Raffai and K. H. Weisgraber Hypomorphic Apolipoprotein E Mice. A NEW MODEL OF CONDITIONAL GENE REPAIR TO EXAMINE APOLIPOPROTEIN E-MEDIATED METABOLISM J. Biol. Chem., March 22, 2002; 277(13): 11064 - 11068. [Abstract] [Full Text] [PDF]

				J. W. Furbee Jr., O. Francone, and J. S. Parks In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice J. Lipid Res., March 1, 2002; 43(3): 428 - 437. [Abstract] [Full Text] [PDF]

				M. B. Elam, H. G. Wilcox, L. M. Cagen, X. Deng, R. Raghow, P. Kumar, M. Heimberg, and J. C. Russell Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat J. Lipid Res., December 1, 2001; 42(12): 2039 - 2048. [Abstract] [Full Text] [PDF]

				M. Merkel, W. Velez-Carrasco, L. C. Hudgins, and J. L. Breslow Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice PNAS, October 16, 2001; (2001) 231490498. [Abstract] [Full Text] [PDF]

				T. Hirano, T. Takahashi, S. Saito, H. Tajima, T. Ebara, and M. Adachi Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E665 - E669. [Abstract] [Full Text] [PDF]

				A. R. Mensenkamp, B. Teusink, J. F.W. Baller, H. Wolters, R. Havinga, K. W. van Dijk, L. M. Havekes, and F. Kuipers Mice Expressing Only the Mutant APOE3Leiden Gene Show Impaired VLDL Secretion Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1366 - 1372. [Abstract] [Full Text] [PDF]

				C. Maugeais, U. J. F. Tietge, K. Tsukamoto, J. M. Glick, and D. J. Rader Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice J. Lipid Res., October 1, 2000; 41(10): 1673 - 1679. [Abstract] [Full Text]

				L. L. Swift, M. H. Farkas, A. S. Major, K. Valyi-Nagy, M. F. Linton, and S. Fazio A Recycling Pathway for Resecretion of Internalized Apolipoprotein E in Liver Cells J. Biol. Chem., June 15, 2001; 276(25): 22965 - 22970. [Abstract] [Full Text] [PDF]

				K. E. Kypreos, K. W. van Dijk, A. van der Zee, L. M. Havekes, and V. I. Zannis Domains of Apolipoprotein E Contributing to Triglyceride and Cholesterol Homeostasis in Vivo. CARBOXYL-TERMINAL REGION 203-299 PROMOTES HEPATIC VERY LOW DENSITY LIPOPROTEIN-TRIGLYCERIDE SECRETION J. Biol. Chem., June 1, 2001; 276(23): 19778 - 19786. [Abstract] [Full Text] [PDF]

				B. Teusink, A. R. Mensenkamp, H. van der Boom, F. Kuipers, K. W. van Dijk, and L. M. Havekes Stimulation of the in Vivo Production of Very Low Density Lipoproteins by Apolipoprotein E Is Independent of the Presence of the Low Density Lipoprotein Receptor J. Biol. Chem., October 26, 2001; 276(44): 40693 - 40697. [Abstract] [Full Text] [PDF]

				M. Merkel, W. Velez-Carrasco, L. C. Hudgins, and J. L. Breslow Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice PNAS, November 6, 2001; 98(23): 13294 - 13299. [Abstract] [Full Text] [PDF]